An Epigenetic Switch Involving NF-kB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation

Tumorigenesis is a multistep process that requires constitutive cell division, growth, and survival. The progression from normal cells to cancer is strongly influenced by environmental conditions and extracellular signaling pathways that affect the activity of tumor...Read More

Boehringer Ingelheim and Priaxon Collaborate to Research and Develop Novel Treatments for Cancer

Boehringer Ingelheim and Priaxon entered into a worldwide collaboration to research ... 

Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet

Bayer Schering Pharma and Micromet announced a global collaboration...

Teva and OncoGenex to Co-develop and Co-commercialize OGX-011

Teva and OncoGenex announced a global license and collaboration agreement...

Ambit Biosciences and Astellas Enter into Strategic Partnership for FLT3 Kinase Inhibitors

Ambit Biosciences and Astellas Pharma
announced a worldwide agreement ...

Clavis Pharma and Clovis Oncology Partner for Anti-Cancer Agent CP-4126

Clavis Pharma and Clovis Oncology announced an agreement for further...

Seattle Genetics Strategically Collaborates with GSK/Millennium and Terminates Agreement with Genentech

Seattle Genetics announced a collaboration agreement with GlaxoSmithKline...

Read More

Tap63 Induces Senescence and Suppresses Tumorigenesis in vivo

Coordination between cellular proliferation and differentiation controls...

TGFβ Signaling Switches Breast Cancer Cells from Cohesive to Single Cell Motility

Regulation of cell motility is important for the metastatic dissemination..

AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

The signal transducer and activator of transcription (Stat) proteins comprise...

Read More

Pfizer Discontinues Phase III Trial of Figitumumab in NSCLC

Pfizer announced the discontinuation of A4021016 (also known as ADVIGO 1016)...

Avastin plus Chemotherapies Improved PFS as 2^nd Treatment in Advanced Breast Cancer

Genentech announced results from a Phase III study (RIBBON 2) of Avastin...

Positive Phase III Trials Results of 1^st and 2^nd line Treatment in CLL

Positive results were reported from 2 Phase III Studies in CLL. Roche announced...

Tasigna Meets Primary Endpoint as 1^st Line Treatment in CML against Glivec

Novartis announced that Tasigna (nilotinib) met its primary endpoint in the first...

Encouraging Response Rates with Carfilzomib in Relapsed/Refractory Multiple Myeloma

Onyx Pharmaceuticals announced results from an ongoing Phase II study...

Read More

At SMARTANALYST, we support the decision-making process for licensing, business development, new product planning, and R&D groups within pharmaceutical and bio tech companies. We currently work with leading pharmaceutical and biotech firms globally.

CLICK HERE to visit SMARTANALYST

A Gene Signature Identifies a Survival Factor in Advanced Ovarian Cancer

Advanced stage ovarian cancer (stages III and IV) often display a heterogeneous...

Excess 2-hydroxyglutarate Contributes to Formation and Progression of Gliomas

The gene encoding the tricarboxylic acid cycle enzyme isocitrate dehydrogenase...

Novel Mutant-selective EGFR Kinase Inhibitors against EGFR T790M

EGFR kinase inhibitors, gefitinib and erlotinib, are effective clinical therapies...

OncoMethylome to Perform MGMT Testing in Roche Phase III Study of Avastin

OncoMethylome Sciences announced that it has entered into an agreement...

Read More

FDA Approves sNDA for Velcade in Patients with Previously Untreated MM

Millennium: The Takeda Oncology Company announced that the FDA...

FDA Extends Review Period for Tarceva Application for 1st Line Maintenance Use in Advanced NSCLC

OSI Pharmaceuticals and Genentech announced that the FDA has extended...

FDA Issues Complete Response for Rituxan in CLL

AGenentech and Biogen Idec announced that the FDA issued a complete response...

Read More